Wednesday, November 19, 2025 11:22:13 AM
lol, now that is hysterical Hoskuld!
It is my obligation to challenge MIsslings statements / actions as a shareholder!
Where did you get that impression? I am challenging Missling's integrity and truthfulness to be believable and hold him to his words. The science always "speaks for itself" in breakthrough biotech especially addressing huge unmet needs. Thats all I need to hear!!
I also found it very telling and fairly obvious that since the entire platform was seemingly stalled out this year, but considering the potential of becomming a commercial pharma company, that there was not even one new hire approaching such a binary event. So I covered all of my avxl shares with calls, in tandem with the latest short attack, plus zero share price run up into anticipation of a good outcome.
So , I'm glad you mentioned sell as that is another of my "options".
If you back check my posts for the past few years, I do sell calls on a percentage of my avxl holdings, and I usually use those georgejjl posts (as he seems to have a finger on the heartbeat of enthusiasm here) as a prompt. Seriously, it worked like a charm over 90% of the time, keeping the premium or waiting a short while if the shares ever were taken to buy them back. Hey, those Novemebr calls were packing very strong premiums right up to the close before the CHMP feedback. I have now sold 1/2 of my avxl position and moved them over to anvs. I believe this space of treating Alzheimers and CNS disease at its earliest stages and addressing the root cause "includes" a few legit comapies / sciences.
It will be interesting how this all plays out and I hope to get the chance to start selling avxl calls again although my core position is a bit smaller.
ps - you sound a bit disgruntled - MIssling do that to you?
It is my obligation to challenge MIsslings statements / actions as a shareholder!
Where did you get that impression? I am challenging Missling's integrity and truthfulness to be believable and hold him to his words. The science always "speaks for itself" in breakthrough biotech especially addressing huge unmet needs. Thats all I need to hear!!
I also found it very telling and fairly obvious that since the entire platform was seemingly stalled out this year, but considering the potential of becomming a commercial pharma company, that there was not even one new hire approaching such a binary event. So I covered all of my avxl shares with calls, in tandem with the latest short attack, plus zero share price run up into anticipation of a good outcome.
So , I'm glad you mentioned sell as that is another of my "options".
If you back check my posts for the past few years, I do sell calls on a percentage of my avxl holdings, and I usually use those georgejjl posts (as he seems to have a finger on the heartbeat of enthusiasm here) as a prompt. Seriously, it worked like a charm over 90% of the time, keeping the premium or waiting a short while if the shares ever were taken to buy them back. Hey, those Novemebr calls were packing very strong premiums right up to the close before the CHMP feedback. I have now sold 1/2 of my avxl position and moved them over to anvs. I believe this space of treating Alzheimers and CNS disease at its earliest stages and addressing the root cause "includes" a few legit comapies / sciences.
It will be interesting how this all plays out and I hope to get the chance to start selling avxl calls again although my core position is a bit smaller.
ps - you sound a bit disgruntled - MIssling do that to you?
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
